(Q27022254)

Henning Blume

series ordinal

2

1 reference

language of work or name

1 reference

April 2014

1 reference

1 April 2014

4 references

20 August 2019

2 October 2019

3 September 2020

30 January 2021

5 references

20 August 2019

2 October 2019

3 September 2020

30 January 2021

37

1 reference

issue

4

1 reference

page(s)

201-11

1 reference

Creative Commons Attribution-NonCommercial 4.0 International

copyright license

start time

19 February 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Drug interaction: omeprazole and phenprocoumon

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Recent safety concerns with proton pump inhibitors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Clopidogrel-drug interactions

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

The potential interaction between clopidogrel and proton pump inhibitors: a systematic review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Drug-drug interaction profiles of proton pump inhibitors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Pharmacokinetic drug interaction profiles of proton pump inhibitors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Proton pump inhibitors and their drug interactions: an evidence-based approach

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Diagnosis and treatment of gastroesophageal reflux disease in the elderly.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Review article: drug interactions with agents used to treat acid-related diseases

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Adverse drug events in high risk older outpatients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Lack of pharmacokinetic interaction of pantoprazole with diazepam in man.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

28 September 2017

Safety of lansoprazole.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

A study of the interaction between omeprazole and cyclosporine in renal transplant patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Lansoprazole does not affect the bioavailability of oral contraceptives

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Clinical Pharmacokinetics of Lansoprazole

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

A study of the interaction of omeprazole and warfarin in anticoagulated patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Oral phenytoin pharmacokinetics during omeprazole therapy

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Lack of influence of pantoprazole on the disposition kinetics of theophylline in man.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Theophylline steady state pharmacokinetics is not altered by omeprazole

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Influence of lansoprazole treatment on diazepam plasma concentrations

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin.

31 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients.

31 May 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

Prokinetics influence the pharmacokinetics of rabeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

Effects of omeprazole on plasma levels of raltegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

The effect of acid reduction with a proton pump inhibitor on the pharmacokinetics of lopinavir or ritonavir in HIV-infected patients on lopinavir/ritonavir-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomized crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation*

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

Pantoprazole does not affect cyclosporin A blood concentration in kidney-transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

Absorption kinetics of levothyroxine is not altered by proton-pump inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin [see comments]

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

Absence of influence of concomitant administration of rabeprazole on the pharmacokinetics of tacrolimus in adult living-donor liver transplant patients: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0144-0

Effects of multiple-dose esomeprazole and pantoprazole on diazepam pharmacokinetic profile and pharmacodynamic effects on cognitive and psychomotor function in healthy volunteers

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Antacids have no influence on the pharmacokinetics of rabeprazole, a new proton pump inhibitor, in healthy volunteers.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3975086

Serum Iron, Ferritin, and Vitamin B12 During Prolonged Omeprazole Therapy

28 November 2018

1 reference

12 December 2020

Lansoprazole and ethanol metabolism: comparison with omeprazole and cimetidine

1 reference

12 December 2020

The effect of pantoprazole on tacrolimus and cyclosporin A blood concentration in transplant recipients

1 reference

12 December 2020

Pantoprazole does not interact with the pharmacokinetics of carbamazepine

1 reference

12 December 2020

The influence of gastrointestinal agents on resorption and metabolism of cyclosporine after heart transplantation: experimental and clinical results

1 reference

12 December 2020

Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments

1 reference

12 December 2020

A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology

1 reference

12 December 2020

Pharmacokinetic interaction between lansoprazole and theophylline

1 reference

12 December 2020

Effect of omeprazole on the pharmacokinetics of itraconazole

1 reference

12 December 2020

Decreased plasma levels of omeprazole after coadministration with magnesium-aluminium hydroxide dry suspension granules

1 reference

12 December 2020

Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial

1 reference

12 December 2020

Lack of pharmacokinetic interaction between oral pantoprazole and cisapride in healthy adults

1 reference

12 December 2020

Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction

1 reference

12 December 2020

Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects

1 reference

12 December 2020

Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol

1 reference

12 December 2020

A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers

1 reference

12 December 2020

Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans

1 reference

12 December 2020

Pantoprazole lacks induction of CYP1A2 activity in man

1 reference

12 December 2020

The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients

1 reference

12 December 2020

Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies

1 reference

12 December 2020

The Effects of Lansoprazole on the Disposition of Antipyrine and Indocyanine Green in Normal Human Subjects

1 reference

12 December 2020

Lack of pharmacodynamic and pharmacokinetic interaction between pantoprazole and phenprocoumon in man

1 reference

12 December 2020

Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test

1 reference

12 December 2020

A study of the interaction between omeprazole and phenytoin in epileptic patients

1 reference

12 December 2020

Omeprazole-cyclosporin interaction

1 reference

12 December 2020

Proton pump inhibitor co-therapy with clopidogrel: is there GI benefit or cardiovascular harm?

1 reference

12 December 2020

Effects of lansoprazole on pharmacokinetics and metabolism of theophylline

1 reference

12 December 2020

Stereoselective interaction of omeprazole with warfarin in healthy men

1 reference

12 December 2020

Pantoprazole does not interact with nifedipine in man under steady-state conditions

1 reference

12 December 2020

Lack of pharmacokinetic interaction between lansoprazole and intravenously administered phenytoin

1 reference

12 December 2020

Effect of omeprazole on bioavailability of an oral extended-release formulation of ciprofloxacin

1 reference

12 December 2020

No influence of pantoprazole on the pharmacokinetics of phenytoin

1 reference

12 December 2020

Lack of pharmacokinetic interaction between pantoprazole and diclofenac

1 reference

12 December 2020

Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers

1 reference

12 December 2020

Pantoprazole has no influence on steady state pharmacokinetics and pharmacodynamics of metoprolol in healthy volunteers

1 reference

12 December 2020

Lack of interaction between pantoprazole and digoxin at therapeutic doses in man

1 reference

12 December 2020

10.1007/S40264-014-0144-0

Identifiers

DOI

1 reference

Dimensions Publication ID

1037134279

0 references

1 reference

1 reference

PubMed publication ID

24550106

1 reference